Gerard Gallagher is an Executive Editor for Healio, a medical news platform. With a focus on infectious diseases and pediatric practice, Gerard covers a wide range of topics including vaccine updates, COVID-19 testing, public health warnings, and advancements in the field of infectious diseases.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Gerard Gallagher’s coverage primarily focuses on healthcare and pharmaceuticals, with a strong emphasis on infectious diseases, public health, medical research, and vaccines. His articles often cite data and provide expert commentary. To effectively reach out to Gerard Gallagher, consider providing insights or data-backed analysis related to developments in the field of infectious diseases or public health. Experts who can offer valuable perspectives on vaccine development or healthcare preparedness for pandemics would likely be of interest to him.
When reaching out to Gerard Gallagher with pitches for potential stories or expert commentary, it's important to ensure that the content aligns closely with his areas of focus within the healthcare sector. Additionally, given his lack of specified geographic focus but broad international themes covered in healthcare and pharmaceutical fields, he may appreciate insights from global experts as well as those focusing specifically on the US context when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The CDC on Wednesday recommended a spring COVID-19 vaccine booster shot for adults aged 65 years or older.
The FDA on Friday approved Rybrevant in combination with chemotherapy as the first first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, Johnson & Johnson announced.The approval converts the May 2021 accelerated approval of Rybrevant (amivantamab-vmjw, Janssen) to a full approval.
As it does every year, the Conference on Retroviruses and Opportunistic Infections is shining a spotlight on emerging research in HIV over the course of 4 days, this year at the Colorado Convention Center in Denver.
By: Gerard Gallagher, Carol L. DiBerardino
DENVER — As clinicians await national guidelines on its use, evidence continues to mount that doxy-PEP can help curtail the prolonged epidemic of sexually transmitted infections in the United States.
By: Jeanne Marrazzo, Gerard Gallagher, Stephen Feller
DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.
DENVER — The International Antiviral Society-USA (IAS-USA) has updated its HIV treatment guidelines to endorse the off-label use of long-acting injectable ART in patients with HIV viremia.
By: Gerard Gallagher, Carol L. DiBerardino
DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.
Researchers have found that AI platforms perform better when given clear, unambiguous prompts. This was the case when clinicians at Rutgers University tested ChatGPT’s ability to create poems that could be used in medical education.
By: Gerard Gallagher, Carol L. DiBerardino
SHEA Spring is back with a new theme: “The Future is Now: Implementing Change through People, Policy and Technology.”
By: Caitlyn Stulpin, Gerard Gallagher, Carol L. DiBerardino
The FDA and U.S. Department of Agriculture (USDA) said this week that pasteurized milk and beef products appear safe for consumption based on testing conducted after traces of avian influenza were found in pasteurized milk.
(833) 317-6278 
